Payment overview · 2025
General Payments
$845.45
40 reported records · 13 companies
Healthcare provider profile · identity verified
Samer S Obri, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DEFIANCE, OH · NPI 1700879657
Verified facts
What the public records show
CMS Open Payments records show Samer S Obri, MD received $845.45 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $208.71 | 24.7% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.62 | 21.7% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $100.92 | 11.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.40 | 8.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.63 | 8.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.31 | 6.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.00 | 5.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.37 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.34 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.09 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.21 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.74 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.11 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $845.45 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $130.55 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $115.31 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $100.92 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.42 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.94 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.94 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.70 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.70 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.01 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.49 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 236 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 247 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
247 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1031 | 318 |
| Gabapentin | Gabapentin | 732 | 179 |
| Omeprazole | Omeprazole | 546 | 160 |
| Pantoprazole Sodium | Pantoprazole Sodium | 535 | 145 |
| Tizanidine Hcl | Tizanidine Hcl | 502 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 483 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 480 | 140 |
| Fluticasone Propionate | Fluticasone Propionate | 455 | 218 |
| Lisinopril | Lisinopril | 431 | 141 |
| Metoprolol Succinate | Metoprolol Succinate | 421 | 123 |
| Metformin Hcl | Metformin Hcl | 380 | 114 |
| Trazodone Hcl | Trazodone Hcl | 364 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 335 | 126 |
| Glimepiride | Glimepiride | 322 | 98 |
| Furosemide | Furosemide | 319 | 113 |
| Tamsulosin Hcl | Tamsulosin Hcl | 309 | 94 |
| Prednisone | Prednisone | 274 | 159 |
| Potassium Chloride | Potassium Chloride | 271 | 80 |
| Carvedilol | Carvedilol | 261 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 261 | 84 |
| Pravastatin Sodium | Pravastatin Sodium | 259 | 78 |
| Allopurinol | Allopurinol | 256 | 75 |
| Ozempic | Semaglutide | 247 | 47 |
| Eliquis | Apixaban | 236 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 57 |
| Meloxicam | Meloxicam | 225 | 79 |
| Losartan Potassium | Losartan Potassium | 222 | 78 |
| Sertraline Hcl | Sertraline Hcl | 204 | 63 |
| Metformin Hcl Er | Metformin Hcl | 201 | 57 |
| Simvastatin | Simvastatin | 197 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 190 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 179 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 59 |
| Cephalexin | Cephalexin | 176 | 141 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 52 |
| Atenolol | Atenolol | 171 | 50 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 166 | 70 |
| Montelukast Sodium | Montelukast Sodium | 161 | 44 |
| Spironolactone | Spironolactone | 149 | 50 |
| Tramadol Hcl | Tramadol Hcl | 148 | 83 |
| Famotidine | Famotidine | 144 | 39 |
| Azithromycin | Azithromycin | 142 | 104 |
| Mirtazapine | Mirtazapine | 130 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 127 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 126 | 102 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 123 | 33 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 115 | 91 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 28 |
| Donepezil Hcl | Donepezil Hcl | 101 | 30 |
| Ezetimibe | Ezetimibe | 100 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 96 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | 30 |
| Buspirone Hcl | Buspirone Hcl | 95 | 25 |
| Pregabalin | Pregabalin | 86 | 32 |
| Jardiance | Empagliflozin | 85 | 24 |
| Xarelto | Rivaroxaban | 84 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 43 |
| Ibuprofen | Ibuprofen | 77 | 38 |
| Nystatin | Nystatin | 76 | 37 |
| Dexamethasone | Dexamethasone | 75 | 66 |
| Propranolol Hcl | Propranolol Hcl | 73 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 19 |
| Alprazolam | Alprazolam | 63 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 24 |
| Bumetanide | Bumetanide | 62 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 62 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 39 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 58 | 20 |
| Meclizine Hcl | Meclizine Hcl | 58 | 46 |
| Nifedipine Er | Nifedipine | 57 | 18 |
| Januvia | Sitagliptin Phosphate | 55 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 45 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 14 |
| Levetiracetam | Levetiracetam | 54 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 12 |
| Finasteride | Finasteride | 49 | 17 |
| Synthroid | Levothyroxine Sodium | 49 | 14 |
| Bupropion Xl | Bupropion Hcl | 48 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 16 |
| Fluconazole | Fluconazole | 48 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 40 |
| Celecoxib | Celecoxib | 45 | 12 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 45 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 14 |
| Clonazepam | Clonazepam | 42 | 11 |
| Topiramate | Topiramate | 42 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 12 |
| Mounjaro | Tirzepatide | 41 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | 11 |
| Mupirocin | Mupirocin | 37 | 20 |
| Nitroglycerin | Nitroglycerin | 37 | 29 |
| Baclofen | Baclofen | 36 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 36 | 13 |
| Levofloxacin | Levofloxacin | 35 | 25 |
| Metronidazole | Metronidazole | 35 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Valsartan | Valsartan | 30 | 12 |
| Warfarin Sodium | Warfarin Sodium | 30 | 11 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | 14 |
| Labetalol Hcl | Labetalol Hcl | 29 | 14 |
| Naproxen | Naproxen | 29 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 28 | 17 |
| Ammonium Lactate | Ammonium Lactate | 27 | 11 |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | 15 |
| Hydrocortisone | Hydrocortisone | 26 | 19 |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 25 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 24 | 13 |
| Colchicine | Colchicine | 22 | suppressed |
| Invokana | Canagliflozin | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Cholestyramine Light | Cholestyramine | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $845.45 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error